Home > Insider Trading > Filing (0001415889-21-001949)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1285819	Omeros Corp	OMER	Pharmaceutical Preparations (2834)	911663741

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1472160	Md A Gregory Demopulos	C/O Omeros Corporation 201 Elliott Avenue West Seattle WA 98119	Chairman, Ceo & President	No	No	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2021-04-07	37,407	$4.10	2,064,393	No	4	M	Direct
Common Stock	Disposition	2021-04-07	37,407	$17.91	2,026,986	No	4	S	Direct
Common Stock	Acquisiton	2021-04-08	35,206	$4.10	2,062,192	No	4	M	Direct
Common Stock	Disposition	2021-04-08	35,206	$17.76	2,026,986	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	M	Direct
No	4	S	Direct
No	4	M	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Stock Option (right to buy)	Disposition	2021-04-07	37,407	$0.00	37,407	$4.10
Common Stock	Stock Option (right to buy)	Disposition	2021-04-08	35,206	$0.00	35,206	$4.10

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
182,632		2022-01-07	No	4	M	Direct
147,426		2022-01-07	No	4	M	Direct

Footnotes

Open market sale pursuant to a previously established Rule 10b5-1 trading plan adopted by the reporting person for expiring options. The trading schedule, including sale periods and the number of shares to be sold, was established at the time of the trading plan's adoption in accordance with Rule 10b5-1 under the Securities Exchange Act of 1934, as amended.
This transaction was executed in multiple trades at prices ranging from $17.53 to $18.27; the price reported above reflects the weighted average sales price. The reporting person hereby undertakes to provide full information regarding the number of shares and prices at which the transactions referenced in this footnote were effected upon request to the SEC staff, the issuer, or a security holder of the issuer.
This transaction was executed in multiple trades at prices ranging from $17.60 to $17.96; the price reported above reflects the weighted average sales price. The reporting person hereby undertakes to provide full information regarding the number of shares and prices at which the transactions referenced in this footnote were effected upon request to the SEC staff, the issuer, or a security holder of the issuer.
The shares subject to this option vested and became exercisable over 48 monthly installments, with a vesting commencement date of April 1, 2011.